DK3158054T3 - Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier - Google Patents

Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier Download PDF

Info

Publication number
DK3158054T3
DK3158054T3 DK15809700.6T DK15809700T DK3158054T3 DK 3158054 T3 DK3158054 T3 DK 3158054T3 DK 15809700 T DK15809700 T DK 15809700T DK 3158054 T3 DK3158054 T3 DK 3158054T3
Authority
DK
Denmark
Prior art keywords
bacteria
genetic
methods
modified
modification
Prior art date
Application number
DK15809700.6T
Other languages
English (en)
Inventor
Thomas Hitchcock
Mun Su Rhee
Original Assignee
Crown Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Laboratories Inc filed Critical Crown Laboratories Inc
Application granted granted Critical
Publication of DK3158054T3 publication Critical patent/DK3158054T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
DK15809700.6T 2014-06-17 2015-06-17 Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier DK3158054T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013159P 2014-06-17 2014-06-17
PCT/US2015/036306 WO2015195845A1 (en) 2014-06-17 2015-06-17 Genetically modified bacteria and methods for genetic modification of bacteria

Publications (1)

Publication Number Publication Date
DK3158054T3 true DK3158054T3 (da) 2025-05-26

Family

ID=54835648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15809700.6T DK3158054T3 (da) 2014-06-17 2015-06-17 Genetisk modificerede bakterier og fremgangsmåder til genetisk modifikation af bakterier

Country Status (12)

Country Link
US (3) US10584344B2 (da)
EP (1) EP3158054B1 (da)
JP (3) JP2017521059A (da)
CN (2) CN118979001A (da)
BR (1) BR112016029581B1 (da)
CA (1) CA2950945A1 (da)
DK (1) DK3158054T3 (da)
ES (1) ES3025685T3 (da)
HU (1) HUE071447T2 (da)
PL (1) PL3158054T4 (da)
SI (1) SI3158054T1 (da)
WO (1) WO2015195845A1 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US20150086581A1 (en) * 2012-03-17 2015-03-26 The Regents Of The University Of California Fast Diagnosis and Personalized Treatment for Acne
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
CN118979001A (zh) 2014-06-17 2024-11-19 皇冠实验室有限公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
WO2016172196A1 (en) 2015-04-20 2016-10-27 Pätzold Bernhard Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
WO2017075260A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
WO2017147507A1 (en) * 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
US20190336542A1 (en) * 2016-04-21 2019-11-07 Naked Biome, Inc. Synthetic bacteria and methods of use
JP2019514885A (ja) 2016-04-21 2019-06-06 ネイキッド バイオーム，インク． 皮膚障害の処置のための組成物および方法
WO2018018010A1 (en) * 2016-07-21 2018-01-25 Metacrine, Inc. Fgf mutants and uses thereof
JP7235654B2 (ja) 2016-10-19 2023-03-08 エス－バイオメディック・ナームローゼ・フェンノートシャップ 細菌株の複合混合物を用いた皮膚マイクロバイオームの組成を変化させる方法および組成物
US20200121744A1 (en) * 2016-11-08 2020-04-23 The Regents Of The University Of California Compositions and methods for treating skin diseases and maintaining healthy skin
WO2018195180A1 (en) * 2017-04-18 2018-10-25 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of enteric bacterial infections and associated pathologies including colorectal cancer
JP7312741B2 (ja) * 2017-07-21 2023-07-21 住友化学株式会社 望ましい遺伝子発現を促進するためのプラスミドアディクションシステム
WO2019079618A2 (en) * 2017-10-20 2019-04-25 Naked Biome, Inc. FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
KR101927988B1 (ko) * 2018-08-23 2018-12-12 주식회사 지놈앤컴퍼니 신규의 큐티박테리움 그래뉼로섬 균주, 및 이러한 균주 또는 이의 배양물을 포함하는 여드름 예방 또는 치료용 조성물
CN109628533A (zh) * 2019-01-18 2019-04-16 重庆派金生物科技有限公司 成纤维细胞生长因子蛋白可溶性高效重组表达的方法
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
CN110244047B (zh) * 2019-06-10 2023-11-03 广州市妇女儿童医疗中心 肺癌血清诊断标志物及其应用、肺癌相关可溶性蛋白的分离鉴定方法
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
CN113092774B (zh) * 2020-01-09 2022-08-19 中国科学院生物物理研究所 mtEF4蛋白作为毛发生长和脱发的生物标志物的用途
CN111440755B (zh) * 2020-04-10 2023-03-10 西北农林科技大学 一株布鲁氏菌S2疫苗株DnaA基因条件性诱导缺失菌株、其构建方法及应用
KR102197174B1 (ko) * 2020-05-08 2020-12-31 코스맥스 주식회사 큐티박테리움 그래뉼로섬 균주 및 그의 피부 상태 개선 용도
BR112022026237A2 (pt) 2020-06-23 2023-01-17 Crown Laboratories Inc Formulações probióticas para a pele
CN112342152B (zh) * 2020-06-28 2022-05-20 南昌大学 一种表达脂肪酶的山羊葡萄球菌株ncu s6
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用
EP4656649A1 (en) * 2023-03-10 2025-12-03 WestVac Biopharma Co., Ltd. Anti-acne recombinant protein vaccine, preparation method, and use
WO2025114477A1 (en) * 2023-11-28 2025-06-05 Epigenica Ab Adaptors for ligation
CN120173837B (zh) * 2025-05-21 2025-12-05 杭州微致生物科技有限公司 痤疮丙酸杆菌vb208基因编辑方法及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
US5837509A (en) * 1992-12-30 1998-11-17 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
US20020072089A1 (en) * 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
FR2780733A1 (fr) 1998-06-25 2000-01-07 Gist Brocades Bv Polynucleotide, vecteur et cellule hote le contenant, polypeptide correspondant, procede pour leur production et leur utilisation
EP1110555A1 (fr) 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Agent anti-adhesion de la flore pathogene de la peau
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP2004528005A (ja) * 2000-08-15 2004-09-16 ファージ バイオテクノロジー コーポレイション 生物学的に活性なタンパク質およびペプチドのファージ依存性超産生
DE60236646D1 (de) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
WO2003033515A1 (en) 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
AU2003276822A1 (en) 2002-03-08 2004-02-02 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
WO2004001022A1 (en) 2002-06-21 2003-12-31 The University Of Newcastle Research Associates (Tunra) Ltd Probiotic propionibacterium jensenii 702
CN101172091B (zh) 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
TWI328612B (en) * 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
WO2006058243A2 (en) 2004-11-24 2006-06-01 Yale University Leishmania antigens and related compositions and uses
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
FR2889057B1 (fr) 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
CN1869238A (zh) * 2006-06-24 2006-11-29 中国人民解放军兰州军区兰州总医院 一种修复溃疡的生物制剂
CN100490941C (zh) 2006-12-19 2009-05-27 丽珠医药集团股份有限公司 一种干燥剂在活菌制剂干燥中的应用
ATE478568T1 (de) 2007-02-02 2010-09-15 May Amadeus Alexander Produkt mit lebenden probiotischen mikroorganismen
FR2915388B1 (fr) 2007-04-27 2010-12-24 Oreal Film hydrosoluble cosmetique
ES2583163T3 (es) 2007-10-02 2016-09-19 Kuhs Gmbh Composición cosmética o farmacéutica para aplicación tópica
KR101489723B1 (ko) * 2008-03-14 2015-02-06 인하대학교 산학협력단 전기천공법을 이용한 프로피오니박테리움 아크네스의형질전환 조건의 최적화
FR2938437B1 (fr) 2008-11-19 2020-03-27 Société des Produits Nestlé S.A. Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
US8557249B2 (en) 2008-11-07 2013-10-15 Solazyme, Inc. Cosmetic compositions comprising microalgal components
GB0821729D0 (en) 2008-11-28 2008-12-31 Plant Bioscience Ltd Composition and method for enhanced secretion of peptides and proteins from bacteria
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
US8496917B2 (en) 2009-11-13 2013-07-30 Sytheon Ltd Compositions and methods for improving skin appearance
EP2501796A4 (en) * 2009-11-18 2012-12-19 Murray Goulburn Coop Co Ltd RECOMBINANT MICROORGANISMS
FR2953408B1 (fr) 2009-12-08 2013-02-08 Oreal Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau
DK2364712T3 (da) 2010-03-11 2013-05-21 Kloarys Invest Ltd Topisk, kosmetisk eller farmaceutisk sammensætning, der omfatter probiotiske Lactobacillus-stammer, og anvendelse heraf
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
JP5954828B2 (ja) * 2010-05-21 2016-07-20 株式会社明治 皮膚状態の改善用組成物
US9713596B2 (en) 2011-02-02 2017-07-25 Unigen, Inc. Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
PL2704704T3 (pl) 2011-05-03 2019-04-30 Dupont Nutrition Biosci Aps Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
JP5866717B2 (ja) 2011-05-31 2016-02-17 コーロン グロテック インコーポレイテッド 人工芝構造体及びその製造方法、並びに製造装置
CN104105471B (zh) 2012-02-14 2018-03-13 宝洁公司 皮肤共生益生元剂和包含其的组合物的局部使用
US20150086581A1 (en) 2012-03-17 2015-03-26 The Regents Of The University Of California Fast Diagnosis and Personalized Treatment for Acne
US20140023618A1 (en) 2012-07-23 2014-01-23 Applied Biology Systems and methods for treatment of androgenetic skin conditions by microbial organisms
AU2013299605A1 (en) 2012-08-07 2015-03-26 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
KR102576903B1 (ko) * 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
US9295723B2 (en) 2013-03-01 2016-03-29 Envy Medical, Inc. Acne solution
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US20160200789A1 (en) * 2013-04-26 2016-07-14 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
US20160264998A1 (en) * 2013-07-26 2016-09-15 Industry Foundation Of Chonnam National University Method for transformation of prokaryote or eukaryote using aminoclay
US20170065647A1 (en) 2014-05-07 2017-03-09 The Regents Of The University Of California Compositions and methods for treating skin and mucous membrane diseases
CN118979001A (zh) 2014-06-17 2024-11-19 皇冠实验室有限公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
US10471035B2 (en) 2014-10-20 2019-11-12 Sunny BioDiscovery Compositions and methods for using esters of meroterpenes and of other resveratrol analogues
US10597402B2 (en) 2015-03-27 2020-03-24 Sytheon Limited Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
US9636292B2 (en) 2015-07-30 2017-05-02 Truth Aesthetics LLC Topical skin care composition for night use
WO2017044835A1 (en) 2015-09-10 2017-03-16 Xycrobe Therapeutics, Inc. Genetically modified bacteria, compositions and methods of making and using
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
JP2019514885A (ja) 2016-04-21 2019-06-06 ネイキッド バイオーム，インク． 皮膚障害の処置のための組成物および方法
US20190336542A1 (en) 2016-04-21 2019-11-07 Naked Biome, Inc. Synthetic bacteria and methods of use
US10568819B2 (en) 2016-10-31 2020-02-25 Sytheon Limited Skin enhancing compositions and methods
US10293237B1 (en) * 2017-08-17 2019-05-21 Callaway Golf Company Putter with alignment aid
US20220000762A1 (en) 2018-11-16 2022-01-06 S-biomedic N.v. Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases

Also Published As

Publication number Publication date
ES3025685T3 (en) 2025-06-09
US20150361436A1 (en) 2015-12-17
US20250002924A1 (en) 2025-01-02
CA2950945A1 (en) 2015-12-23
EP3158054A1 (en) 2017-04-26
BR112016029581A2 (pt) 2017-10-24
CN118979001A (zh) 2024-11-19
CN106661543A (zh) 2017-05-10
US12049633B2 (en) 2024-07-30
EP3158054A4 (en) 2017-11-15
JP2021006528A (ja) 2021-01-21
US10584344B2 (en) 2020-03-10
SI3158054T1 (sl) 2025-06-30
PL3158054T3 (pl) 2025-07-21
HUE071447T2 (hu) 2025-08-28
BR112016029581B1 (pt) 2022-05-03
US20200115717A1 (en) 2020-04-16
WO2015195845A1 (en) 2015-12-23
JP6913216B2 (ja) 2021-08-04
PL3158054T4 (pl) 2025-07-21
EP3158054B1 (en) 2025-02-19
JP2021169490A (ja) 2021-10-28
JP2017521059A (ja) 2017-08-03

Similar Documents

Publication Publication Date Title
HUE071447T2 (hu) Genetikailag módosított baktériumok és eljárások baktériumok genetikai módosítására
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3240785T3 (da) Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3152956T3 (da) Systemer og metoder til kommunikation
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3134149T3 (da) Mikrokanyler og fremgangsmåder til fremstilling deraf
DK3151859T3 (da) Virkningsfuld og effektiv kontrol af serumphosphat til optimal knogledannelse
DK3220973T3 (da) Kunstigt lungesystem og fremgangsmåder til anvendelse deraf
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3377653T3 (da) Fremgangsmåder til opnåelse og korrektion af biologisk sekvensinformation
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling